All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 vaccine,CpG 1018
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: CEPI
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Funding December 29, 2020
Details:
CEPI will initially contribute up to $5m toward the cost of scaling up the process for manufacturing the COVAX, and will explore providing additional funding to Bio E with the goal of potentially enabling the production of 100 million doses in 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ZyCoV-D
Therapeutic Area: Infections and Infectious Diseases Product Name: ZyCoV-D
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 24, 2020
Details:
Zydus Cadila's ZyCoV-D', has been found to be safe and immunogenic in the Phase I/II clinical trials, and the company is seeking regulatory approval to commence Phase-III trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Covid-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Bayer college of medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2020
Details:
Company said in November it had started early-stage and mid-stage human trials of its vaccine candidate, being developed in collaboration with Baylor College of Medicine in Houston and U.S.-based Dynavax Technologies Corp, and expects results by February 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 vaccine,CpG 1018
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: International Finance Corporation
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Funding December 17, 2020
Details:
International Finance Corporation has invested $30 million, or about Rs 221 crore, in Indian vaccine maker Biological E to help the latter expand its range of low-priced, generic vaccines for routine immunisation of children and new vaccines including future Covid-19 vaccine.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 vaccine,CpG 1018
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Dynavax Technologies
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
BE's Phase I/II clinical trial will evaluate the safety and immunogenicity of the vaccine candidate consisting of the Receptor Binding Domain of the Spike Protein of SARS-CoV-2 at three dose levels adjuvanted with CpG 1018 plus alum, in about 360 healthy adult subjects.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ZyCoV-D
Therapeutic Area: Infections and Infectious Diseases Product Name: ZyCoV-D
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2020
Details:
Zydus Cadila is expected to test its Covid vaccine candidate, ZyCoV-D, on about 30,000 people in the Phase-3 trials that it plans to start next month.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tetravalent recombinant chimeric Dengue vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: DengiAll
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
Details:
DengiAll has illustrated the strength of Panacea Biotec’s expertise in vaccinology, research, development, and manufacturing while leveraging NIH’s ability to work on complex biological challenges to develop breakthrough technologies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NVX-COV2373,Matrix-M
Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Gavi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 08, 2020
Details:
The collaboration will support SII to increase manufacturing capacity nowso that,once a vaccine, or vaccines,gains regulatory approvaland WHO prequalification, doses can be produced at scale for distributionto India and LMIC as part of the Gavi COVAX AMC mechanism.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ZyCoV-D
Therapeutic Area: Infections and Infectious Diseases Product Name: ZyCoV-D
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2020
Details:
Zydus Cadila's plasmid DNA vaccine to prevent COVID-19, ZyCoV-D was found to be safe and well tolerated in the Phase I clinical trial. The company will now commence Phase II clinical trials
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BBV152
Therapeutic Area: Infections and Infectious Diseases Product Name: Covaxin
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2020
Details:
Human trial with Corona vaccine (COVAXIN) of Bharat Biotech started at PGI Rohtak.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
